CRBU
QTTB

Timothy P. Kelly

Known title: See Remarks.CIK: 0001754067

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 29, 2026

No recent news for Caribou Biosciences (CRBU). There are no recent news releases specifically about Caribou Biosciences in the past week. The stock remains unchanged in terms of public announcements. Technical indicators show RSI at 35.1 and support around $1.59, but without new information the market context is limited.

this person other insiders at CRBU

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 25, 2026

Q32 Bio to Present Late‑Breaking Results of Bempikibart Trial at EADV Congress. Q32 Bio will present late‑breaking results from Part B of its SIGNAL‑AA Phase 2a study of Bempikibart for alopecia areata at the European Academy of Dermatology and Venereology Congress. The company also shared additional 36‑week data from the same study earlier in the congress. These updates provide new information on the drug’s safety and efficacy profile, which may influence market perception of the company’s pipeline.

this person other insiders at QTTB

Transaction History

CRBU▼ Sell$12K
CRBU▼ Sell$6K
CRBU▲ Buy$0
CRBU▲ Buy$0
QTTB▼ Sell$5K
QTTB▲ Buy—
QTTB▼ Sell$416

We use analytics to understand how market-wall is used. No personal data is sold.